Monte Rosa Therapeutics/$GLUE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Ticker
$GLUE
Sector
Primary listing
Employees
142
Headquarters
Website
GLUE Metrics
BasicAdvanced
$761M
41.88
$0.29
1.42
-
Price and volume
Market cap
$761M
Beta
1.42
52-week high
$12.44
52-week low
$3.50
Average daily volume
1.3M
Financial strength
Current ratio
7.155
Quick ratio
7
Long term debt to equity
13.816
Total debt to equity
15.343
Profitability
EBITDA (TTM)
23.296
Gross margin (TTM)
31.77%
Net profit margin (TTM)
13.58%
Operating margin (TTM)
8.40%
Effective tax rate (TTM)
14.97%
Revenue per employee (TTM)
$1,250,000
Management effectiveness
Return on assets (TTM)
2.66%
Return on equity (TTM)
9.81%
Valuation
Price to earnings (TTM)
41.875
Price to revenue (TTM)
5.686
Price to book
2.84
Price to tangible book (TTM)
2.84
Price to free cash flow (TTM)
42.43
Free cash flow yield (TTM)
2.36%
Free cash flow per share (TTM)
0.29
Growth
Revenue change (TTM)
2,990.57%
Earnings per share change (TTM)
-113.42%
3-year earnings per share growth (CAGR)
-47.30%
What the Analysts think about GLUE
Analyst ratings (Buy, Hold, Sell) for Monte Rosa Therapeutics stock.
Bulls say / Bears say
Novartis agreement announced September 15, 2025 provides up to $5.7 billion in collaboration funding with a $120 million upfront payment, significantly strengthening Monte Rosa’s financial runway and validating its immunology pipeline (Reuters).
Clinical data from the Phase 1 SAD/MAD study of MRT-6160 in March 2025 demonstrated a favorable safety and pharmacokinetic profile, enabling advancement into multiple Phase 2 studies for immune-mediated diseases (GlobeNewswire).
Updated Phase 1/2 data for MRT-2359 in March 2025 showed encouraging signals of clinical response in heavily pretreated castration-resistant prostate cancer patients, focusing development on a high-unmet-need indication (GlobeNewswire).
Monte Rosa’s net cash declined by $46 million in Q1 2025 and by a further $35.5 million in Q2 2025, underscoring sustained high R&D-driven operational burn despite collaboration revenues (GlobeNewswire, GlobeNewswire).
Monte Rosa’s reliance on milestone-driven collaboration revenue—non-recurring and recognized upfront—skews reported profitability and leaves core pre-revenue operations dependent on future partnership milestones (GlobeNewswire).
Key program MRT-8102 only entered Phase 1 in July 2025, with initial proof-of-concept data not expected until H1 2026, delaying near-term clinical catalysts (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2025.
GLUE Financial Performance
Revenues and expenses
GLUE Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Monte Rosa Therapeutics stock?
Monte Rosa Therapeutics (GLUE) has a market cap of $761M as of October 28, 2025.
What is the P/E ratio for Monte Rosa Therapeutics stock?
The price to earnings (P/E) ratio for Monte Rosa Therapeutics (GLUE) stock is 41.88 as of October 28, 2025.
Does Monte Rosa Therapeutics stock pay dividends?
No, Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders as of October 28, 2025.
When is the next Monte Rosa Therapeutics dividend payment date?
Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders.
What is the beta indicator for Monte Rosa Therapeutics?
Monte Rosa Therapeutics (GLUE) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.